Complement activation in the arteries of patients with severe atherosclerosis

Xiaowen Ge1, Chen Xu1, Yalan Liu1

  • 1Department of Pathology, Zhongshan Hospital, Fudan University Shanghai, P. R. China.

Insights

Complement activation, indicated by C3b/iC3b and membrane attack complex (MAC) deposition, is linked to atherosclerosis (AS). Higher levels correlate with hypertension and hypertriglyceridemia, suggesting a role in AS development.

Area of Science:

  • Immunology
  • Cardiovascular Disease
  • Pathogenesis of Atherosclerosis

Background:

  • Excessive complement system activation is implicated in atherosclerosis (AS) pathogenesis.
  • Investigated complement activation in AS lesions by detecting C3b/iC3b and membrane attack complex (MAC) deposition.
  • Analyzed correlations between complement deposition levels and patient clinicopathological features.

Purpose of the Study:

  • To determine if complement is activated in atherosclerotic arteries.
  • To quantify C3b/iC3b and MAC deposition in AS lesions.
  • To explore the relationship between complement activation markers and clinical characteristics of AS patients.

Main Methods:

  • Immunohistochemistry (IHC) used to evaluate C3b/iC3b and MAC deposition in 79 AS patients.
  • Deposition levels were scored and correlated with recorded clinical features.
  • Comparison made between AS arteries and normal arteries.

Main Results:

  • Significantly increased C3b/iC3b and MAC deposits observed in AS arteries versus normal arteries.
  • Higher C3b/iC3b deposition correlated with a greater prevalence of hypertension.
  • Increased MAC deposition was associated with a higher prevalence of hypertriglyceridemia.

Conclusions:

  • C3b/iC3b and MAC deposition confirm complement activation in atherosclerotic arteries.
  • Elevated deposition suggests excessive complement activation contributes to AS development.
  • Hypertension and hypertriglyceridemia may be linked to complement C3 activation and MAC formation, respectively.
Abstract

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
389
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
247
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
701
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
280
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
9.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
309